Valneva (NASDAQ:VALN) Shares Gap Up – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $6.30, but opened at $6.60. Valneva shares last traded at $6.67, with a volume of 8,909 shares trading hands.

Wall Street Analyst Weigh In

VALN has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. TD Cowen began coverage on Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Valneva currently has a consensus rating of “Hold” and an average price target of $9.30.

Valneva Stock Performance

The stock has a fifty day moving average of $5.55 and a 200-day moving average of $6.70. The stock has a market cap of $620.58 million, a PE ratio of -3.10 and a beta of 1.77. The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The company had revenue of $39.37 million for the quarter, compared to analysts’ expectations of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. On average, equities analysts forecast that Valneva SE Sponsored ADR will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently added to or reduced their stakes in VALN. Marex Group plc acquired a new stake in shares of Valneva in the 2nd quarter valued at approximately $64,000. JPMorgan Chase & Co. acquired a new position in Valneva during the third quarter worth $124,000. Finally, XTX Topco Ltd acquired a new position in Valneva during the fourth quarter worth $94,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.